30Jun 2021
Cemiplimab is a new option in BCC

Cemiplimab is a new option in BCC

The Hedgehog inhibitor vismodegib is a standard-of-care agent for patients with locally advanced or metastatic basal cell carcinomas (BCCs), although most will eventually have disease progression. BCCs are among the cancer types with a higher tumour mutational burden and, thus, immune-checkpoint inhibitors might have clinical activity in this setting...

  • #oncology

Like

Save

Share